Cardiovascular News & Analysis
2 articles
Market Mood
Novo Nordisk (NVO) Shares Fall 9% After Heart Drug Trial Fails
Novo Nordisk shares fell by as much as 10% following a statement regarding a late-stage trial of the heart drug ziltivekimab, which failed to significantly reduce major cardiovascular events when compared to a placebo. The company reported a decline of 8.6% in Copenhagen and 9.8% in premarket trading in the U.S. despite some biological effects observed. The chief scientific officer, Martin Holst Lange, affirmed the company's ongoing commitment to cardiovascular disease research. This news is important as it may impact investor confidence and stock performance for Novo Nordisk (NVO).
Read More: Novo Nordisk (NVO) Shares Fall 9% After Heart Drug Trial Fails
Lilly (LLY) obesity pill reduces cardiovascular risks in trial
Eli Lilly (LLY) announced that its Foundayo obesity pill met its trial goals by reducing the risk of major cardiovascular events by 16% in over 2,700 adults with type 2 diabetes. Compared to insulin glargine, patients taking Foundayo experienced a 57% lower risk of death from any cause. Additionally, those on Foundayo had greater reductions in blood sugar and weight, unlike patients on insulin glargine who gained weight. Eli Lilly plans to seek U.S. approval for Foundayo for type 2 diabetes by the end of Q2.
Read More: Lilly (LLY) obesity pill reduces cardiovascular risks in trial